Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 SEK | -0.68% | +1.10% | -30.33% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.33% | 6.97M | - | ||
-2.25% | 89.08B | A- | ||
+3.55% | 40.9B | A- | ||
-14.40% | 32.25B | B- | ||
+55.89% | 25.14B | A | ||
-15.96% | 15.39B | C | ||
-15.50% | 11.91B | B- | ||
-41.29% | 11.89B | B | ||
-11.75% | 11.64B | D+ | ||
+7.87% | 9.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EXPRS2 Stock
- Ratings ExpreS2ion Biotech Holding AB